Literature DB >> 1468159

Kidney transplantation in Alport's syndrome: long-term outcome and allograft anti-GBM nephritis.

J Göbel1, C J Olbricht, G Offner, U Helmchen, H Repp, K M Koch, U Frei.   

Abstract

Anti-glomerular basement membrane (anti-GBM) nephritis occurring in kidneys transplanted in patients with Alport's syndrome (AS) has been reported repeatedly. Therefore, we studied graft survival and course of renal function in all 30 AS patients grafted at Hannover Medical School and compared them with non-diabetic, age and sex matched patients, transplanted on the date closest to the transplantation of the AS patient. Serum creatinine, proteinuria, urinary sediment and anti-GBM antibodies were examined in all AS patients with functioning grafts. Cases of patient or graft loss in the AS group were analyzed retrospectively. One- and five-year patient survival was 100 and 91% in AS and 89 and 78% in controls (p > 0.05, respectively). One- and five-year first graft survival was 79 and 66% in both groups. Graft histology was available in 34 biopsies obtained from 21 kidneys in 15 AS patients. Anti-GBM nephritis was not detected in any of the biopsies. No graft was lost due to anti-GBM nephritis. Anti-GBM antibodies were detectable temporarily only in one AS patient. He also had linear IgG staining in his graft GBM, but no other signs of anti-GBM nephritis. We conclude that patient survival and graft survival in AS patients following kidney transplantation is not different from non-AS patients. Allograft anti-GBM nephritis is a rare complication in patients with Alport's syndrome.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1468159

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  7 in total

Review 1.  Glomerular disease of transplanted kidneys.

Authors:  U Frei
Journal:  Clin Investig       Date:  1993-10

2.  Evaluation of Genetic Kidney Diseases in Living Donor Kidney Transplantation: Towards Precision Genomic Medicine in Donor Risk Assessment.

Authors:  Yasar Caliskan; Brian Lee; Adrian Whelan; Fadee Abualrub; Krista L Lentine; Arksarapuk Jittirat
Journal:  Curr Transplant Rep       Date:  2022-03-16

Review 3.  Approach to genetic testing to optimize the safety of living donor transplantation in Alport syndrome spectrum.

Authors:  Yasar Caliskan; Krista L Lentine
Journal:  Pediatr Nephrol       Date:  2022-01-27       Impact factor: 3.651

4.  Genotype and Outcome After Kidney Transplantation in Alport Syndrome.

Authors:  Valentine Gillion; Karin Dahan; Jean-Pierre Cosyns; Pascale Hilbert; Michel Jadoul; Eric Goffin; Nathalie Godefroid; Martine De Meyer; Michel Mourad; Yves Pirson; Nada Kanaan
Journal:  Kidney Int Rep       Date:  2018-02-02

Review 5.  How benign is hematuria? Using genetics to predict prognosis.

Authors:  Daniel P Gale
Journal:  Pediatr Nephrol       Date:  2013-01-17       Impact factor: 3.714

6.  A Case of Alport Syndrome with Posttransplant Antiglomerular Basement Membrane Disease despite Negative Antiglomerular Basement Membrane Antibodies by EIA Treated with Plasmapheresis and Intravenous Immunoglobulin.

Authors:  Sumiko I Armstead; Thomas Hellmark; Jorgen Wieslander; Xin J Zhou; Ramesh Saxena; Nilum Rajora
Journal:  Case Rep Transplant       Date:  2013-12-02

Review 7.  Therapeutic apheresis in kidney transplantation: An updated review.

Authors:  Maurizio Salvadori; Aris Tsalouchos
Journal:  World J Transplant       Date:  2019-10-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.